


204060-22CT500T



COPY OF PAPERS
ORIGINALLY FILED



C: I P E J C 178
 SEP 04 2002
 PATENT & TRADEMARK OFFICE

COPY OF PAPER
 ORIGINALLY FILED




FIG. 2

204060-22EFS001

SEP 04 2002
O.I.F.E. JC-178
PATENT & TRADEMARK OFFICE

FIG. 3



COPY OF PAPERS
ORIGINALLY FILED

204060-22E15001






FIG. 4



COPY OF PAPERS
ORIGINALLY FILED



204060-22CT5001



COPY OF PAPERS
ORIGINALLY FILED




FIG. 5




FIG. 6

204060-22ET500T




FIG. 7




FIG. 8

204060-22215001

10051322-090402




FIG. 9





FIG. 10

204060-22ET500F



COPY OF PAPERS
ORIGINALLY FILED



204060-22ET5001

204060-22ET5007



COPY OF PAPERS
ORIGINALLY FILED




FIG. 12




FIG. 13



COPY OF PAPERS
ORIGINALLY FILED

204060-22ET500T





FIG. 14



204060-22ET500T




FIG. 15




FIG. 16



COPY OF PAPERS
ORIGINALLY FILED




FIG. 17A

204069-22ET5001




FIG. 17B






FIG. 17C

204060-22ET5001





COPY OF PAPERS
ORIGINALLY FILED




FIG. 17F




FIG. 17G

204060-22ET500T

10051322-090402



COPY OF PAPERS
ORIGINALLY FILED




FIG. 17H



COPY OF PAPERS
ORIGINALLY FILED




FIG. 17I




FIG. 17J

204060-22275001



COPY OF PAPERS
ORIGINALLY FILED




FIG. 18




FIG. 19




FIG. 20




FIG. 21

204060-22E500F



204060-22EFS001

COPY OF PAPERS
ORIGINALLY FILED




FIG. 22



COPY OF PAPERS
ORIGINALLY FILED




FIG. 23A




FIG. 23B

204060-22275001




FIG. 23C




FIG. 24

204060-22ET500T



COPY OF PAPERS
ORIGINALLY FILED

204060-22ET5001








FIG. 25



1. The first group of patients (Group I) consisted of 10 patients who had been treated with a combination of 5-fluorouracil and leucovorin for advanced colorectal cancer. The patients were treated with 5-fluorouracil 500 mg/m² intravenously (i.v.) over 24 hours, followed by leucovorin 50 mg/m² i.v. over 15 minutes, every 2 weeks for 6 cycles. The patients were then treated with the same regimen for 6 more cycles. The patients were then treated with the same regimen for 6 more cycles. The patients were then treated with the same regimen for 6 more cycles.



COPY OF PAPERS
ORIGINALLY FILED




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 31a




FIG. 33




FIG. 34

204060-22E1500T



COPY OF PAPERS
ORIGINALLY FILED




FIG. 35

204060-22ET500T



COPY OF PAPERS
ORIGINALLY FILED




FIG. 36




FIG. 37

204060-22215001



COPY OF PAPERS
ORIGINALLY FILED




FIG. 38




FIG. 39

204060-2215001



COPY OF PAPERS
ORIGINALLY FILED




FIG. 40




FIG. 41

204060-222F5001